Status:
RECRUITING
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Bronchiectasis
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations). T...
Eligibility Criteria
Inclusion
- Male or female participants. Woman of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per International Council of Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1 % per year when used consistently and correctly, as well as one barrier method. A list of contraception methods meeting these criteria is provided in the participant information.
- Signed and dated written informed consent and assent, if applicable, prior to admission to the study, in accordance with GCP and local legislation.
- Age of participants when signing the informed consent/assent ≥12 years.
- \-- Adolescents need to weigh at least 35 kg at Visit 1.
- Clinical history consistent with bronchiectasis (e.g. cough, chronic sputum production, recurrent respiratory infections) and investigator confirmed diagnosis of bronchiectasis by CT scan where bronchiectasis has been documented by a radiologist.
- Participants whose past CT scan image records are not available will undergo a chest CT scan during Screening. Historical scans must not be older than five years.
- Adult participants should be able to produce sputum for Pseudomonas aeruginosa assessment during the screening period.
- History of documented pulmonary exacerbations requiring antibiotic treatment. In the 12 months before Visit 1, participants must have had either:
- at least 2 exacerbations, or
- at least 1 exacerbation and an St. George's Respiratory Questionnaire (SGRQ) Symptoms score of \>40 at screening Visit 1 (adults only)
- at least 1 exacerbation and high symptom burden according to the investigator's judgement (adolescents only) For participants on oral or inhaled antibiotics as chronic treatment for bronchiectasis and participants on Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy (CFTR-MT), at least one exacerbation must have occurred since initiation of antibiotics or CFTR-MT.
Exclusion
- Any new or newly diagnosed condition of primary or secondary immunodeficiency within 1 year before randomisation.
- Allergic bronchopulmonary aspergillosis being treated or requiring treatment.
- Tuberculosis or non-tuberculosis mycobacterial infection being treated or requiring treatment
- Any findings in the medical examination and/or laboratory value assessed at Screening Visit 1 or during screening period, that in the opinion of the investigator may put the participant at risk by participating in the trial.
- Any clinically relevant (at the discretion of the investigator) acute respiratory infection or ongoing pulmonary exacerbation at screening visit or during the screening unless recovered in the opinion of the investigator prior to Visit 2.
- Any relevant pulmonary, gastrointestinal, hepatic, renal, cardiovascular, metabolic, immunological, hormonal, or other disorder that, in the opinion of the investigator, may put the participant at risk by participating in the study.
- Major surgery (major according to the investigator's assessment) performed within 6 weeks prior to randomisation or scheduled during trial period.
- Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated in situ non-melanoma skin cancers or in situ carcinoma of uterine cervix.
- Evidence or medical history of moderate or severe liver disease (Child-Pugh score B or C hepatic impairment).
- estimated Glomerular Filtration Rate (eGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (adults) or Chronic Kidney Disease Under 25 (CKiD-U25) (adolescents) \<30 mL/min at Visit 1.
- Previous treatment with a dipeptidyl peptidase-1 (DPP1) (Cathepsin C (CatC)) inhibitor. (Note: Participants that were randomised and only received placebo in studies with DPP1 (CatC) inhibitor are allowed.) Further exclusion criteria apply.
Key Trial Info
Start Date :
June 9 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 12 2028
Estimated Enrollment :
1755 Patients enrolled
Trial Details
Trial ID
NCT06872892
Start Date
June 9 2025
End Date
October 12 2028
Last Update
March 5 2026
Active Locations (497)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
2
Providence Medical Group Alaska
Anchorage, Alaska, United States, 99508
3
Dignity Health, St. Joseph's Hospital and Medical Center
Phoenix, Arizona, United States, 85013
4
University of Arizona
Tucson, Arizona, United States, 85724